| This article has been cited by |
| 1 | | |
| Katherine Dunnington,Natacha Benrimoh,Christine Brandquist,Nadia Cardillo-Marricco,Mike Di Spirito,Julie Grenier |
| .2018;() |
| [DOI] |
|
| 2 | A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes | |
| Susanna Dodd,Ian R. White,Paula Williamson |
| Trials.2017;18(1) |
| [DOI] |
|
| 3 | A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes | |
| Susanna Dodd,Ian R. White,Paula Williamson |
| Trials.2020;18(1)21 |
| [DOI] |
|
| 4 | Commentary on Apathy as a Model for Investigating Behavioral and Psychological Symptoms in Dementia | |
| Andrea Gilmore-Bykovskyi |
| Journal of the American Geriatrics Society.2018;66(S1)21 |
| [DOI] |
|
| 5 | Process evaluation of a randomised controlled trial of PBS-based staff training for challenging behaviour in adults with intellectual disability | |
| Alessandro Bosco,Laura Paulauskaite,Ian Hall,Jason Crabtree,Sujata Soni,Asit Biswas,Vivien Cooper,Michaela Poppe,Michael King,Andre Strydom,Michael J. Crawford,Angela Hassiotis,Rosemary Frey |
| PLOS ONE.2019;14(8)e0221507 |
| [DOI] |
|
| 6 | The benefits of covariate adjustment for adaptive multi-arm designs | |
| Kim May Lee,David S. Robertson,Thomas Jaki,Richard Emsley |
| Statistical Methods in Medical Research.2022;31(11)2104 |
| [DOI] |
|
| 7 | Challenges in Evaluating Safety and Efficacy in Drug Development for Rare Diseases: A Review for Pharmacists | |
| Kanya K. Shah,Stephen Kogut,Angela Slitt |
| Journal of Pharmacy Practice.2021;34(3)472 |
| [DOI] |
|
| 8 | Blinding, sham, and treatment effects in randomized controlled trials for back pain in 2000–2019: A review and meta-analytic approach | |
| Brian Freed,Brian Williams,Xiaolu Situ,Victoria Landsman,Jeehyoung Kim,Alex Moroz,Heejung Bang,Jongbae J Park |
| Clinical Trials.2021;18(3)361 |
| [DOI] |
|
| 9 | Cannabis and regulatory science: A review of challenges in Africa | |
| Zimunda Nyazema Norman |
| African Journal of Pharmacy and Pharmacology.2023;17(3)52 |
| [DOI] |
|
| 10 | Including non-concurrent control patients in the analysis of platform trials: is it worth it? | |
| Kim May Lee,James Wason |
| BMC Medical Research Methodology.2020;20(1)52 |
| [DOI] |
|
| 11 | Including non-concurrent control patients in the analysis of platform trials: is it worth it? | |
| David Hong,Pedro C. Barata |
| BMC Medical Research Methodology.2018;20(1)47 |
| [DOI] |
|
| 12 | Indian Pharmaceutical Industries Current Status and Togetherness to Overcome Speed Breakers in Term of Quality Issues to make India as a Global Pharma Destination | |
| Vikas Rathee,Kapil Pihwal,Neelam Pawar,Sheikh Aamir,Mohammad S. Alam,Kavita Bahmani |
| Applied Drug Research, Clinical Trials and Regulatory Affairs.2021;8(1)19 |
| [DOI] |
|
| 13 | Cardiovascular Nursing Science Priorities | |
| Mariann R. Piano,Nancy T. Artinian,Holli A. DeVon,Susan T. Pressler,Kathleen T. Hickey,Deborah A. Chyun |
| Journal of Cardiovascular Nursing.2018;33(4)E11 |
| [DOI] |
|
| 14 | Adaptive Design of Clinical Trials: A Sequential Learning Approach | |
| Zhengli Wang,Stefanos Zenios |
| SSRN Electronic Journal.2020;33(4)E11 |
| [DOI] |
|
| 15 | Brain Organoids: Tiny Mirrors of Human Neurodevelopment and Neurological Disorders | |
| Anuradha Yadav,Brashket Seth,Rajnish Kumar Chaturvedi |
| The Neuroscientist.2021;27(4)388 |
| [DOI] |
|
| 16 | Timely evaluation in international development | |
| Jayne Webster,Josephine Exley,James Copestake,Rick Davies,James Hargreaves |
| Journal of Development Effectiveness.2018;10(4)482 |
| [DOI] |
|
| 17 | Applying concepts from “rapid” and “agile” implementation to advance implementation research | |
| Andrew Quanbeck,Rose Garza Hennessy,Linda Park |
| Implementation Science Communications.2022;3(1)482 |
| [DOI] |
|
| 18 | Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine | |
| Elliott Antman,Scott Weiss,Joseph Loscalzo |
| WIREs Systems Biology and Medicine.2012;4(4)367 |
| [DOI] |
|
| 19 | Shuffling Adaptive Clinical Trials | |
| Sanjay G. Gokhale,Sankalp Gokhale |
| American Journal of Therapeutics.2016;23(3)e663 |
| [DOI] |
|
| 20 | Shuffling Adaptive Clinical Trials | |
| Gerfried K.H. Nell |
| American Journal of Therapeutics.2018;23(3)383 |
| [DOI] |
|
| 21 | Shuffling Adaptive Clinical Trials | |
| Peter G. Stock,Rita Mukhtar,Hila Ghersin,Allison Stover Fiscalini,Laura Esserman |
| American Journal of Therapeutics.2020;23(3)59 |
| [DOI] |
|
| 22 | Shuffling Adaptive Clinical Trials | |
| Kristiana Salmon,Angela Genge |
| American Journal of Therapeutics.2021;23(3)161 |
| [DOI] |
|
| 23 | Shuffling Adaptive Clinical Trials | |
| Sarah J. Trenfield,Christine M. Madla,Abdul W. Basit,Simon Gaisford |
| American Journal of Therapeutics.2018;31(3)1 |
| [DOI] |
|
| 24 | RCTs and other clinical trial designs in Ayurveda: A review of challenges and opportunities | |
| Pushya A. Gautama |
| Journal of Ayurveda and Integrative Medicine.2021;12(3)556 |
| [DOI] |
|
| 25 | RCTs and other clinical trial designs in Ayurveda: A review of challenges and opportunities | |
| Zhaoling Meng |
| Journal of Ayurveda and Integrative Medicine.2022;12(3)169 |
| [DOI] |
|
| 26 | Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review | |
| Dionysios Palermos,Theodoros N. Sergentanis,Maria Gavriatopoulou,Panagiotis Malandrakis,Theodora Psaltopoulou,Evangelos Terpos,Ioannis Ntanasis-Stathopoulos |
| Journal of Clinical Medicine.2022;11(23)7176 |
| [DOI] |
|
| 27 | Unique Study Designs in Nephrology: N-of-1 Trials and Other Designs | |
| Joyce P. Samuel,Cynthia S. Bell |
| Advances in Chronic Kidney Disease.2016;23(6)351 |
| [DOI] |
|
| 28 | Nutzenbewertung von digitalen Gesundheitsprodukten (Digital Health) im gesellschaftlichen Erstattungskontext | |
| Urs-Vito Albrecht,Bertolt Kuhn,Jörg Land,Volker E. Amelung,Ute von Jan |
| Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.2018;61(3)340 |
| [DOI] |
|
| 29 | Nutzenbewertung von digitalen Gesundheitsprodukten (Digital Health) im gesellschaftlichen Erstattungskontext | |
| Gunasakaran Sambandan,Adina Turcu-Stiolica |
| Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.2019;61(3)323 |
| [DOI] |
|
| 30 | Nutzenbewertung von digitalen Gesundheitsprodukten (Digital Health) im gesellschaftlichen Erstattungskontext | |
| Semran B. Thamer,Sean Liu,Afshin E. Razi |
| Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.2023;61(3)295 |
| [DOI] |
|
| 31 | Nutzenbewertung von digitalen Gesundheitsprodukten (Digital Health) im gesellschaftlichen Erstattungskontext | |
| Nancy E. Jones |
| Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.2022;61(3)226 |
| [DOI] |
|
| 32 | Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation | |
| Myrto Lee,Hoan Ly,Clemens C. Möller,Michael S. Ringel |
| Clinical Pharmacology & Therapeutics.2019;105(4)886 |
| [DOI] |
|
| 33 | The ethical justification for inclusion of neonates in pragmatic randomized clinical trials for emergency newborn care | |
| Dan Kabonge Kaye |
| BMC Pediatrics.2019;19(1)886 |
| [DOI] |
|
| 34 | Adaptive trial design: Its growing role in clinical research and implications for pharmacists | |
| Joshua Cirulli,Wesley D. McMillian,Mojdeh Saba,David Stenehjem |
| American Journal of Health-System Pharmacy.2011;68(9)807 |
| [DOI] |
|
| 35 | Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies | |
| Qing Li,Jianchang Lin,Yunzhi Lin |
| Contemporary Clinical Trials.2020;98(9)106096 |
| [DOI] |
|
| 36 | Examining Tensions That Affect the Evaluation of Technology in Health Care: Considerations for System Decision Makers From the Perspective of Industry and Evaluators | |
| Laura Desveaux,James Shaw,Ross Wallace,Onil Bhattacharyya,R Sacha Bhatia,Trevor Jamieson |
| JMIR Medical Informatics.2017;5(4)e50 |
| [DOI] |
|
| 37 | Examining Tensions That Affect the Evaluation of Technology in Health Care: Considerations for System Decision Makers From the Perspective of Industry and Evaluators | |
| Suresh Kumar |
| JMIR Medical Informatics.2021;5(4)735 |
| [DOI] |
|
| 38 | How can attrition rates be reduced in cancer drug discovery? | |
| Lucas Moreno,Andrew DJ Pearson |
| Expert Opinion on Drug Discovery.2013;8(4)363 |
| [DOI] |
|
| 39 | PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints | |
| Tian He,Rachael Liu,Meizi Liu,Jianchang Lin |
| Journal of Biopharmaceutical Statistics.2022;32(4)567 |
| [DOI] |
|
| 40 | Clinical trial considerations for pediatric cancer drug development | |
| Freda Cooner,Jingjing Ye,Gregory Reaman |
| Journal of Biopharmaceutical Statistics.2023;32(4)1 |
| [DOI] |
|
| 41 | Governance of adaptive platform trials | |
| Jerome Amir Singh |
| Wellcome Open Research.2023;8(4)141 |
| [DOI] |
|
| 42 | Drug development challenges and strategies to address emerging and resistant fungal pathogens | |
| Matthew W. McCarthy,Thomas J. Walsh |
| Expert Review of Anti-infective Therapy.2017;15(6)577 |
| [DOI] |
|
| 43 | Drug development challenges and strategies to address emerging and resistant fungal pathogens | |
| Margaret S. Landis |
| Expert Review of Anti-infective Therapy.2017;25(6)297 |
| [DOI] |
|
| 44 | Assessing the ability of adaptive designs to capture trends in hard coral cover | |
| AWLP Thilan,P Menéndez,JM McGree |
| Environmetrics.2023;34(6)297 |
| [DOI] |
|
| 45 | Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT | |
| Sudeep Pushpakom,Ruwanthi Kolamunnage-Dona,Claire Taylor,Terry Foster,Catherine Spowart,Marta Garcia-Finana,Graham J Kemp,Thomas Jaki,Saye Khoo,Paula Williamson,Munir Pirmohamed |
| Efficacy and Mechanism Evaluation.2019;6(6)1 |
| [DOI] |
|
| 46 | Adaptive clinical trials in public health emergency contexts: ethics considerations | |
| Jerome Amir Singh |
| Wellcome Open Research.2023;8(6)130 |
| [DOI] |
|
| 47 | Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment | |
| Norah A. Alturki |
| Journal of Clinical Medicine.2023;12(13)4301 |
| [DOI] |
|
| 48 | An investigation of the impact of futility analysis in publicly funded trials | |
| Benjamin GO Sully,Steven A Julious,Jon Nicholl |
| Trials.2014;15(1)4301 |
| [DOI] |
|
| 49 | Computational Drug Repurposing: Current Trends | |
| Berin Karaman,Wolfgang Sippl |
| Current Medicinal Chemistry.2019;26(28)5389 |
| [DOI] |
|
| 50 | Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review | |
| Miranta Antoniou,Andrea L Jorgensen,Ruwanthi Kolamunnage-Dona,H. Peter Soyer |
| PLOS ONE.2016;11(2)e0149803 |
| [DOI] |
|
| 51 | Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review | |
| Ruitao Lin,J. Jack Lee |
| PLOS ONE.2020;11(2)395 |
| [DOI] |
|
| 52 | Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective | |
| Elja Arjas,Dario Gasbarra |
| BMC Medical Research Methodology.2022;22(1)395 |
| [DOI] |
|
| 53 | Progress, development, and challenges in amyotrophic lateral sclerosis clinical trials | |
| Jasmine F. Ashhurst,Sicong Tu,Hannah C. Timmins,Matthew C. Kiernan |
| Expert Review of Neurotherapeutics.2022;22(11-12)905 |
| [DOI] |
|
| 54 | Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial | |
| Franck Pires Cerqueira,Angelo Miguel Cardoso Jesus,Maria Dulce Cotrim |
| Therapeutic Innovation & Regulatory Science.2019;22(11-12)216847901983124 |
| [DOI] |
|
| 55 | Applications of artificial intelligence and machine learning in heart failure | |
| Tauben Averbuch,Kristen Sullivan,Andrew Sauer,Mamas A Mamas,Adriaan A Voors,Chris P Gale,Marco Metra,Neal Ravindra,Harriette G C Van Spall |
| European Heart Journal - Digital Health.2022;3(2)311 |
| [DOI] |
|
| 56 | The Future Role of the United States in Global Health | |
| Valentin Fuster,Jendayi Frazer,Megan Snair,Rajesh Vedanthan,Victor Dzau,Jendayi Frazer,Valentin Fuster,Gisela Abbam,Amie Batson,Frederick Burkle,Lynda Chin,Lia Haskin Fernald,Stephanie Ferguson,Peter Lamptey,Ramanan Laxminarayan,Michael Merson,Vasant Narasimhan,Michael Osterholm,Juan Carlos Puyana |
| Journal of the American College of Cardiology.2017;70(25)3140 |
| [DOI] |
|
| 57 | Implications of comparative effectiveness research for radiation oncology | |
| Justin E. Bekelman,Anand Shah,Stephen M. Hahn |
| Practical Radiation Oncology.2011;1(2)72 |
| [DOI] |
|
| 58 | Electronic Health Interventions for Patients With Breast Cancer: Systematic Review and Meta-Analyses | |
| Anna C. Singleton,Rebecca Raeside,Karice K. Hyun,Stephanie R. Partridge,Gian Luca Di Tanna,Nashid Hafiz,Qiang Tu,Justin Tat-Ko,Stephanie Che Mun Sum,Kerry A. Sherman,Elisabeth Elder,Julie Redfern |
| Journal of Clinical Oncology.2022;40(20)2257 |
| [DOI] |
|
